Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSC-200-A0201
- Development stage
- Phase 1
- Lead developer
- TCRx Therapeutics
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TSC-200-A0201 is an autologous, enhanced T cell receptor-engineered T cell (TCR-T) therapy developed by TScan Therapeutics for the treatment of solid tumors associated with human papillomavirus type 16 (HPV16). The therapy utilizes a naturally occurring, high-avidity TCR specific for the HPV16 E7 antigen presented on HLA-A*02:01. Engineered patient-derived CD4+ and CD8+ T cells are modified to express this cancer antigen-specific TCR, along with co-expressed CD8α/β to enhance helper function and a dominant negative form of transforming growth factor beta receptor II (DN-TGFβRII) to promote persistence in the immunosuppressive tumor microenvironment. Preclinical studies demonstrated potent target-dependent cytotoxicity, cytokine secretion, proliferation, and anti-tumor efficacy in vitro and in vivo. The product is designed as part of a multiplexed approach (T-Plex), allowing combination with other engineered TCR-Ts targeting different antigens/HLA types based on individual tumor biology[6][7][8].
- Brand names
- TSC-200-A0201TSC200-A0201TSC 200-A0201
- Other names
- TSC-200-A0201TSC200-A0201TSC 200-A0201TSC-200TSC200TSC 200
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on TSC-200-A0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSC-200-A0201.